Arcus Biosciences obtains loan facility with Hercules Capital worth $250m
Arcus turned to Hercules Capital’s financing for support and to advance its HIF-2α inhibitor casdatifan.
Arcus turned to Hercules Capital’s financing for support and to advance its HIF-2α inhibitor casdatifan.
What's Your Reaction?
